ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aclaris Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.48+0.20 (+6.10%)
Close on Oct 19, 2026
- Market cap
- $496.72M
- P/E (TTM)
- –
- Dividend yield
- –
Aclaris Therapeutics, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Single reportable segment | $7.83M | $18.72M | – | – | – | – | – | – | – | – | 100.0% | -58.2% |
| Therapeutics Segment | – | $16.18M | $28.21M | $25.36M | $932.00K | $696.00K | – | $1.50M | – | – | – | – |
| Contract Research Segment | – | $2.54M | $3.04M | $12.61M | $7.62M | $13.32M | $16.82M | $13.14M | $3.20M | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Single reportable segment | -$76.38M | -$141.93M | – | – | – | – | – | – | – | – | -46.2% |
| Therapeutics Segment | – | -$120.34M | -$65.56M | -$65.88M | -$67.67M | -$31.47M | -$84.42M | -$60.92M | -$36.11M | -$36.93M | – |
| Contract Research Segment | – | -$3.43M | -$3.94M | -$2.35M | -$1.49M | -$1.70M | -$2.17M | -$445.00K | -$197.00K | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Licensing | $5.95M | $16.18M | $28.21M | $25.10M | $809.00K | $690.00K | – | – | – | – | 76.1% | -63.2% |
| Contract research | $1.87M | $2.54M | $3.04M | $4.40M | $5.83M | $5.79M | $4.23M | $4.65M | $1.68M | – | 23.9% | -26.3% |
| Other | – | – | – | $257.00K | $122.00K | $6.00K | – | $1.50M | – | – | – | – |
| Product sales, net | – | – | – | – | – | – | – | $3.94M | – | – | – | – |
| ESKATA | – | – | – | – | – | – | – | $2.80M | – | – | – | – |
| RHOFADE | – | – | – | – | – | – | – | $1.14M | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Aclaris Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.